ResMed Inc. (NYSE:RMD) is an undervalued stock, exceeding the earnings expectations and posting a strong 52% profit jump.
Ieq Capital LLC and
Alberta Investment Management Corp increased their position in the company. Despite a drop in its organic sales growth, it is considered a wise choice due to 'mega trends'. The prominent institutional backing, standing at about
69%, makes ResMed a strong momentum stock. The company has managed to score better-than-expected sales in Q4 revenue and is inching close to join a very elite stock group. Its Q2 2025 earnings call underline its strong financial performance amid the global crisis.
AustralianSuper Pty Ltd and
Chicago Capital LLC boosted their holdings in ResMed, and the company received positive rating upgrades. Despite challenges, it is considered fully valued, with
J.P. Morgan Healthcare Conference presentation and strong Q2 results underlining the growing demand for sleep apnea solutions. However, some insiders sold shares from the company hinting at potential weakness despite the company beating the Q1 estimates in fiscal 2025. The company recently announced its first fabric
CPAP therapy mask, and the Q2 FY2025 earnings reported revenue surpassing estimates.
Resmed RMD News Analytics from Mon, 24 Jun 2024 07:00:00 GMT to Fri, 21 Feb 2025 12:11:36 GMT -
Rating 7
- Innovation -3
- Information 6
- Rumor -5
